Journal reference: Nihashi, Y., et al. (2022) Identification of a Novel Osteogenetic Oligodeoxynucleotide (osteoDN) That Promotes Osteoblast Differentiation in a TLR9-Independent Manner.

More information: Rena Ikeda et al, Osteogenic CpG Oligodeoxynucleotide, iSN40, Inhibits Osteoclastogenesis in a TLR9-Dependent Manner, Life (2024). DOI: 10.3390/life14121572 ...

Identification of osteogenetic oligodeoxynucleotide that promotes bone differentiation Peer-Reviewed Publication Shinshu University image: osteoDN enhances bone differentiation of osteoblasts.

Osteoporosis, characterized by an imbalance in bone remodeling, is a growing health concern worldwide. Previous research has highlighted the role of osteogenic CpG oligodeoxynucleotide (iSN40) in ...

Thoracic Oncology August 20, 2008 Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for ...

PURPOSE: Preclinical animal experiments support the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor (IGF-IR/AS ODN) as an effective potential ...

Manuscript Open access Published: 10 September 2008 Off-target response to decoy oligodeoxynucleotide treatment Ewan Robson, Aaron Jeffs & Michael Eccles Nature Precedings (2008) Cite this article ...

Original Article Published: 25 June 2012 Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice Hai-yan Du, Li-hou Dong, Bi-jun Zhao, Jie Fu, Qing-qing ...